Nancy Fabiola Diaz Martinez

Nancy Fabiola Diaz Martinez

Auto-generated profile, based on publicly available information

Nancy Fabiola Diaz Martinez

Hospital Mac

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2025 in IECCMEXICO
Verified
Journal Article
Open access
PDF file
GCGenaro Escobar Cruz
Genaro Escobar Cruz
KHKarla Leslie Martínez Hernández
Karla Leslie Martínez Hernández
NONicole Vanessa Larrea Ortiz
Nicole Vanessa Larrea Ortiz
JCJosé Arnulfo Perez Carrillo
José Arnulfo Perez Carrillo
NMNancy Fabiola Diaz Martinez
Nancy Fabiola Diaz Martinez
DMDarime Galatea Orduña Mérida
Darime Galatea Orduña Mérida
Immunologic and inflammatory skin disorders have undergone a profound conceptual transformation over the past two decades. Conditions such as psoriasis, atopic dermatitis, autoimmune blistering diseases, and cutaneous lupus erythematosus are now understood as immune-mediated entities driven by specific pathogenic pathways rather than solely morphologic diagnoses. This review synthesizes contemporary high-impact literature to analyze emerging diagnostic and therapeutic paradigms, emphasizing the transition from broad immunosuppression to mechanism-informed precision targeting. Particular attention is given to the IL-23/Th17 axis in psoriasis, type 2 inflammation in atopic dermatitis, and autoantibody-mediated mechanisms in blistering disorders. The review further compares cytokine-specific biologics with intracellular pathway modulators such as JAK inhibitors, highlighting distinctions in monitoring requirements, breadth of immunologic impact, and practical considerations. A structured therapeutic sequencing model is proposed, integrating clinical severity, immunologic alignment, safety monitoring, and healthcare feasibility. Special consideration is given to implementation in diverse international contexts, including Mexico, Colombia, and Ecuador. The findings support a unified framework in which diagnosis remains clinically grounded but conceptually reinforced by immunopathogenesis, and treatment selection is increasingly guided by targeted immune modulation. This paradigm reflects the broader evolution of translational medicine and underscores the necessity of adaptable, evidence-based strategies in inflammatory dermatology.

28 December 2025 in International Science Journal
Verified
Journal Article
Open access
PDF file
GCGenaro Escobar Cruz
Genaro Escobar Cruz
KHKarla Leslie Martínez Hernández
Karla Leslie Martínez Hernández
NONicole Vanessa Larrea Ortiz
Nicole Vanessa Larrea Ortiz
ATArmando Nolasco Toledo
Armando Nolasco Toledo
NMNancy Fabiola Diaz Martinez
Nancy Fabiola Diaz Martinez
DRDiana Flores Rios
Diana Flores Rios
Cutaneous oncology has entered a new phase defined by the integration of early detection strategies, molecular risk stratification, and biologically guided systemic therapies. Melanoma, although less frequent than keratinocyte cancers, remains the most lethal form of skin cancer, while basal cell carcinoma and Merkel-cell carcinoma contribute significantly to global oncologic burden. This review analyzes the contemporary transformation of cutaneous oncology within the precision medicine framework, focusing on three core domains: stage-based prognosis, genomic characterization, and targeted and immune-based therapeutic interventions. Evidence from landmark clinical trials demonstrates that BRAF-mutated melanoma benefits from combined BRAF/MEK inhibition, while immune checkpoint blockade—particularly PD-1–based regimens—achieves durable survival in advanced disease. Long-term survival data confirm sustained benefit in a subset of patients, redefining expectations for metastatic melanoma outcomes. In addition, immunotherapy has shown meaningful activity in other aggressive cutaneous malignancies such as Merkel-cell carcinoma. The integration of staging systems, molecular diagnostics, and systemic therapies illustrates a dual therapeutic paradigm in which tumor genotype and immune context guide treatment selection. From an international perspective, including healthcare systems in Mexico, Colombia, and Ecuador, the implementation of precision oncology requires structured integration of early detection, standardized pathology, essential genomic testing, and multidisciplinary therapeutic access. Cutaneous oncology in the precision era is therefore characterized by coordinated biological insight and clinical application, forming the basis for advanced academic instruction and evidence-based oncologic practice.